MedTrace Logo

Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks

NCT04253132 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-02-05

No results posted yet for this study

Summary

This is a 12-week study of oral tolfenamic acid vs. placebo in Progressive Supranuclear Palsy (PSP)

Conditions

Interventions

DRUG

Tolfenamic Acid

Tolfenamic acid is an NSAID closely resembling mefenamic and flufenamic acid.

DRUG

Placebos

oral placebo

Sponsors & Collaborators

  • The Cleveland Clinic

    collaborator OTHER

  • NeuroTau, Inc.

    lead OTHER

Principal Investigators

  • Nasser Zawia, PhD · NeuroTau, Inc.

  • Marwan Sabbagh, MD · NeuroTau, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04253132 on ClinicalTrials.gov